about
Antidepressants for the treatment of depression in people with cancerAntidepressants for the treatment of depression in patients with cancerAntipsychotic Dose Mediates the Association between Polypharmacy and Corrected QT IntervalDoes formulation matter? A systematic review and meta-analysis of oral versus long-acting antipsychotic studies.Can We Identify the Active Ingredients of Behaviour Change Interventions for Coronary Heart Disease Patients? A Systematic Review and Meta-AnalysisMaking the use of psychotropic drugs more rational through the development of GRADE recommendations in specialist mental healthcare.Efficacy and acceptability of antidepressants on the continuum of depressive experiences in patients with cancer: Systematic review and meta-analysis.Vortioxetine for depression in adults.New EMA report on paliperidone 3-month injections: taking clinical and policy decisions without an adequate evidence base.Antipsychotic drug exposure and risk of myocardial infarction.Implementation of treatment guidelines for specialist mental health care.Antipsychotic combinations in schizophrenia.First-generation antipsychotics and QTc: any role for mediating variables?Prevalence and correlates of QTc prolongation in Italian psychiatric care: cross-sectional multicentre study.Mapping the evidence on pharmacological interventions for non-affective psychosis in humanitarian non-specialised settings: a UNHCR clinical guidance.Public health psychopharmacology: a new research discipline comes of age?Autism spectrum disorders: weighing the risk of SSRI exposure in pregnancy.Can a digital medicine system improve adherence to antipsychotic treatment?SSRI plus supportive care more effective than supportive care alone for mild to moderate depressionAntidepressants for the treatment of depression in people with cancerFactors associated with first- versus second-generation long-acting antipsychotics prescribed under ordinary clinical practice in ItalyComparative effectiveness of long-acting antipsychotics: issues and challenges from a pragmatic randomised studyAntipsychotic use and risk of life-threatening medical events: umbrella review of observational studiesEsketamine clinical trials: reply to Maju et alPoor implementation of the EU clinical trial regulation is a major threat for pragmatic trials in European countries
P50
Q24187358-8C3721A1-766B-4201-9512-3820F4D399D6Q24198949-35424652-CF94-4C35-89EA-F123A53D8E98Q28553078-472A1986-46A9-444A-940B-0D539CD1B773Q34545159-078A7CA2-1B06-4C03-8DAD-91A6067310A6Q35997119-DD39A5C2-49AB-4D1D-83DF-43C36450EE98Q36843320-1F197E18-D454-4992-ABD5-93886CE87F3AQ38539258-976E675A-AE80-44E2-9ACF-21F4E6E37189Q38693309-9EF3A784-BED2-4EEC-9397-76D9B2A254D1Q38779397-396D547B-68C9-4DE3-97CD-9A710F81A880Q39016420-FC05BD78-497F-45CC-82C9-624FDD4ED9C9Q39039245-228A6080-3E03-4E5D-9A6D-EF24CFF5DC2AQ39348889-4B325B54-CD62-448B-B66B-64B3EAAF35E1Q39721569-4968FED0-B124-47E3-A2A2-AF020D347016Q40431985-6DABF294-8E20-4EEE-8E8A-9EE05EA5BE0FQ47100336-0568070C-E4A1-45C0-93AC-AC0A5BED966CQ47557019-CF663896-9CCE-4CC0-B87A-BB613524C9F6Q50307230-270D0DAC-9174-4E31-ADBA-85B53B1570C7Q52661294-45091F4D-7C35-43F9-8060-E71C7B226332Q57542425-2E3126DA-6A6A-44C5-BE5A-2B66A9854474Q57689353-AE55432A-B60C-4216-B585-3CC861B5D1F4Q58803803-5472879C-B4F4-464A-AE36-41BB80667DBDQ86584536-B6D77B19-A0CB-4508-8D20-B8DCB5343571Q91543881-B97B54A9-812D-4B53-B864-FFF495871211Q94451007-01F52171-73EC-44DF-B15B-6412F313F982Q94547697-EA77634C-361A-425E-AF26-22C237B5B5B5
P50
description
onderzoeker
@nl
researcher ORCID ID = 0000-0003-2248-9524
@en
name
Giovanni Ostuzzi
@ast
Giovanni Ostuzzi
@en
Giovanni Ostuzzi
@es
Giovanni Ostuzzi
@nl
type
label
Giovanni Ostuzzi
@ast
Giovanni Ostuzzi
@en
Giovanni Ostuzzi
@es
Giovanni Ostuzzi
@nl
prefLabel
Giovanni Ostuzzi
@ast
Giovanni Ostuzzi
@en
Giovanni Ostuzzi
@es
Giovanni Ostuzzi
@nl
P106
P1153
35739057200
P21
P31
P496
0000-0003-2248-9524